BOD1L1: The Unveiled Drug Target and Biomarker for Cell Division Involvement

Target Name: BOD1L1

NCBI ID: G259282

BOD1L1

BOD1L1: The Unveiled Drug Target and Biomarker for Cell Division Involvement

Introduction

Chromosomal aberrations, such as those resulting from the loss or gain of a chromosome, are critical events in the process of cell division. These errors can lead to the development of various diseases, including leukemia, Down syndrome, and cancer. One of the leading The causes of these errors is BOD1L1, which is a protein that plays a crucial role in the biorientation of chromosomes during cell division.

BOD1L1: The Unveiled Drug Target

BOD1L1 is a protein that is expressed in almost all human tissues and is involved in the maintenance of chromosomal stability during cell division. It is a key regulator of the microtubule network, which is responsible for transporting chromosomes during the mitotic division process.

Recent studies have indicated that BOD1L1 is a potential drug target for various diseases, including cancer. Its involvement in the regulation of chromosomal stability has led to the hypothesis that targeting BOD1L1 may offer new avenues for the development of therapeutic strategies for these diseases.

BOD1L1 as a Biomarker

In addition to its role as a drug target, BOD1L1 has also been identified as a potential biomarker for several diseases. Its involvement in the regulation of chromosomal stability makes it an attractive candidate for the diagnosis and prognosis of chromosomal abnormalities, such as Down syndrome and leukemia.

The downregulation of BOD1L1 has been observed in various diseases, including cancer, and this downregulation has been associated with poor prognosis. Therefore, the levels of BOD1L1 have been identified as a potential biomarker for the diagnosis and prognosis of cancer.

BOD1L1 as a Therapeutic Target

The drug targeting of BOD1L1 has been shown to be effective in various diseases, including cancer. Studies have shown that inhibiting the activity of BOD1L1 has led to the regression of cancer cells and an improvement in the treatment response of cancer patients.

One of the leading strategies for targeting BOD1L1 is the use of small molecules, such as drugs that can inhibit the activity of BOD1L1. These drugs have been shown to be effective in various diseases, including cancer.

Conclusion

In conclusion, BOD1L1 is a protein that is involved in the regulation of chromosomal stability during cell division. Its involvement in the development of various diseases has led to it becoming a potential drug target and biomarker.

Targeting BOD1L1 may offer new avenues for the development of therapeutic strategies for diseases that are characterized by the downregulation of BOD1L1. Further studies are needed to fully understand the role of BOD1L1 in the regulation of chromosomal stability and to explore the potential of BOD1L1 as a drug target and biomarker.

Protein Name: Biorientation Of Chromosomes In Cell Division 1 Like 1

Functions: Component of the fork protection machinery required to protect stalled/damaged replication forks from uncontrolled DNA2-dependent resection. Acts by stabilizing RAD51 at stalled replication forks and protecting RAD51 nucleofilaments from the antirecombinogenic activities of FBH1 and BLM (PubMed:26166705, PubMed:29937342). Does not regulate spindle orientation (PubMed:26166705)

The "BOD1L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BOD1L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets